- Algernon (AGN) subsidiary, Algernon NeuroScience, has named David Brody to its advisory board
- Brody previously served as the Washington University site director for the National Football League’s neurological player care program
- As an advisor, Brody will consult on Algernon NeuroScience’s clinical research program for the treatment of traumatic brain injury with AP-188 (N,N-Dimethyltryptamine or DMT)
- Algernon Pharmaceuticals is a Canadian clinical-stage drug development company with active research programs for IPF, chronic cough, and chronic kidney disease
- Algernon Pharmaceuticals (AGN) opened with a loss of 2.41 per cent, trading at $1.62 per share
Algernon (AGN) subsidiary, Algernon NeuroScience, has named David Brody to its advisory board.
Brody is a board-certified neurologist with both a research and a clinical specialization in traumatic brain injury (TBI) and neurodegenerative diseases.
He previously served as the Washington University site director for the National Football League’s neurological player care program.
He is currently the Editor-in-Chief of the Journal of Neurotrauma and a member of the editorial board of Acta Neuropathologica.
As an advisor, Brody will consult on Algernon NeuroScience’s clinical research program for the treatment of TBI with AP-188 (N,N-Dimethyltryptamine or DMT).
“Algernon has identified a novel approach to potentially treat TBI patients focused on neuroplasticity, which would be welcome in a clinical environment without any approved pharmacological options,” stated Brody. “I am excited to help further the science and work with them on advancing the DMT research TBI program through clinical trials.”
Algernon NeuroScience is a private equity subsidiary of Algernon Pharmaceuticals advancing the company’s DMT stroke and TBI research program.
Algernon Pharmaceuticals is a Canadian clinical-stage drug development company with active research programs for IPF, chronic cough, and chronic kidney disease.
Algernon Pharmaceuticals (AGN) opened with a loss of 2.41 per cent, trading at $1.62 per share.
